What is the 13F Pro Quality Score for RZLT?

13F Pro ranks Rezolute, Inc. (RZLT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RZLT's current score at https://13fpro.ai/research/RZLT (free sign-up required for the full ranking).

Which hedge funds own the most RZLT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RZLT include FEDERATED HERMES,, RA CAPITAL MANAGEMENT, L.P., BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RZLT as soon as new 13F filings post.

Where does 13F Pro source RZLT data?

All Rezolute, Inc. fundamentals and ownership data come directly from SEC EDGAR. Rezolute, Inc. files with the SEC under CIK 1509261. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RZLT in?

Rezolute, Inc. (RZLT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RZLT research updated on 13F Pro?

RZLT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Rezolute, Inc.(RZLT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1509261 RZLT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RZLT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Rezolute, Inc. (RZLT), a Healthcare sector company. RZLT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), Rezolute, Inc. reports net income of $-16.2M, free cash flow of $-13.7M. Top institutional holders of RZLT by reported 13-F value include FEDERATED HERMES,, RA CAPITAL MANAGEMENT, L.P., BlackRock,, based on the most recent SEC filings. RZLT trades on the Nasdaq exchange and files with the SEC under CIK 1509261. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RZLT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rezolute, Inc. directly from SEC EDGAR.

Net Income

Q3 2026

$-16.2M

Free Cash Flow

Q3 2026

$-13.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-227.5% YoY

$-68.5MFY 2024

FY19 $30.4MFY20 $20.3MFY21 $-20.9MFY24 $-68.5M

Operating Income

-207.6% YoY

$-70.4MFY 2024

FY19 $-25.9MFY20 $-20.5MFY21 $-22.9MFY24 $-70.4M

EPS (Diluted)

+51.1% YoY

$-1.33FY 2024

FY19 —FY20 —FY21 $-2.72FY24 $-1.33

Total Assets

+211.5% YoY

$132.7MFY 2024

FY19 $12.3MFY20 $11.0MFY21 $42.6MFY24 $132.7M

Total Debt

—FY 2024

FY19 $0.00FY20 $0.00FY21 $14.0MFY24 —

Op. Cash Flow

-180.7% YoY

$-57.4MFY 2024

FY19 $-15.3MFY20 $-24.2MFY21 $-20.4MFY24 $-57.4M

Metric	FY 2024	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Net Income	$-68.5M -227.5%	$-20.9M -203.0%	$20.3M -33.2%	$30.4M +201.8%	$-29.9M -47.3%	$-20.3M
Operating Income	$-70.4M -207.6%	$-22.9M -11.6%	$-20.5M +20.9%	$-25.9M +9.7%	$-28.7M -41.4%	$-20.3M
EPS (Diluted)	$-1.33 +51.1%	$-2.72	—	—	—	—
Total Assets	$132.7M +211.5%	$42.6M +288.6%	$11.0M -10.5%	$12.3M +389.5%	$2.5M -76.5%	$10.6M
Total Debt	—	$14.0M	$0.00	$0.00 -100.0%	$3.4M	—
Operating Cash Flow	$-57.4M -180.7%	$-20.4M +15.4%	$-24.2M -57.9%	$-15.3M -8.4%	$-14.1M -6.0%	$-13.3M

AI Insight: RZLT Financial Trends

Rezolute remains unprofitable with no revenue reported; equity erosion accelerating as cash burn persists.

• Operating cash outflow consistently negative, ranging $14–22M quarterly; no improvement trajectory evident across eight quarters.

• Equity declined from $121M (Q2 2024) to $117M (Q1 2026), compressing 3.3% over eight quarters amid persistent losses.

• Operating losses ranged $17–26M per quarter; latest quarter (Q1 2026) at $17M, roughly middle of historical range.

⚠ Equity spiked to $162M in Q2 2025 (likely financing event), then declined 28% by Q1 2026—sustainability uncertain.

⚠ No revenue reported across all eight quarters; absence of top-line growth or clinical milestone visibility.

AI Insight: RZLT Ratio Trends

Rezolute remains deeply unprofitable with negative returns across all metrics; Q1 2026 shows marginal improvement but company is cash-consumptive.

• ROIC improved from -97.0% in Q1 2025 to -59.5% in Q1 2026, though remains deeply negative.

• ROE and ROA show sequential improvement Q4 2025 to Q1 2026 (-71.2% to -55.4% and -65.7% to -51.6%), but losses persist.

⚠ Q1 2025 saw ROIC collapse to -97.0%—worst quarter in dataset—indicating severe operational stress or one-time charges.

⚠ All return metrics remain negative; no clear path to profitability visible in trailing data.

Get alerted when RZLT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rezolute, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RZLT

FEDERATED HERMES, INC.
$39.6M12,990,659 sh
RA CAPITAL MANAGEMENT, L.P.
$28.0M9,180,000 sh
BlackRock, Inc.
$19.3M6,313,503 sh
Opaleye Management Inc.
$19.2M6,300,000 sh
BALYASNY ASSET MANAGEMENT L.P.
$15.4M5,048,421 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.7M3,522,080 sh
JENNISON ASSOCIATES LLC
$10.5M3,438,881 sh
Siren, L.L.C.
$10.2M3,328,287 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$9.1M2,981,765 sh
BANK OF AMERICA CORP /DE/
$9.1M2,970,549 sh

Fund	Value	Shares
FEDERATED HERMES, INC.	$39.6M	12,990,659
RA CAPITAL MANAGEMENT, L.P.	$28.0M	9,180,000
BlackRock, Inc.	$19.3M	6,313,503
Opaleye Management Inc.	$19.2M	6,300,000
BALYASNY ASSET MANAGEMENT L.P.	$15.4M	5,048,421
VANGUARD CAPITAL MANAGEMENT LLC	$10.7M	3,522,080
JENNISON ASSOCIATES LLC	$10.5M	3,438,881
Siren, L.L.C.	$10.2M	3,328,287
VANGUARD PORTFOLIO MANAGEMENT LLC	$9.1M	2,981,765
BANK OF AMERICA CORP /DE/	$9.1M	2,970,549

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RZLT on your watchlist

Track score changes the day Rezolute, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RZLT a good stock to buy?

13F Pro's AI-powered analysis of Rezolute, Inc. (RZLT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RZLT are available on the RZLT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RZLT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RZLT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rezolute, Inc.'s investment landscape.